MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1371/journal.pone.0035363

Медицинская библиотека · PloS one · 2012

Performance of survivin mRNA as a biomarker for bladder cancer in the prospective study UroScreen.

Johnen Georg, Gawrych Katarzyna, Bontrup Heike, Pesch Beate, Taeger Dirk, Banek Séverine, Kluckert Matthias, Wellhäußer Harald, Eberle Friedhelm, Nasterlack Michael, Leng Gabriele, Stenzl Arnulf, Brüning Thomas, UroScreen Study Group

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Urinary biomarkers have the potential to improve the early detection of bladder cancer. Most of the various known markers, however, have only been evaluated in studies with cross-sectional design. For proper validation a longitudinal design would be preferable. We used the prospective study UroScreen to evaluate survivin, a potential biomarker that has multiple functions in carcinogenesis.

METHODS/

RESULTS

Survivin was analyzed in 5,716 urine samples from 1,540 chemical workers previously exposed to aromatic amines. The workers participated in a surveillance program with yearly examinations between 2003 and 2010. RNA was extracted from urinary cells and survivin was determined by Real-Time PCR. During the study, 19 bladder tumors were detected. Multivariate generalized estimation equation (GEE) models showed that β-actin, representing RNA yield and quality, had the strongest influence on survivin positivity. Inflammation, hematuria and smoking did not confound the results. Survivin had a sensitivity of 21.1% for all and 36.4% for high-grade tumors. Specificity was 97.5%, the positive predictive value (PPV) 9.5%, and the negative predictive value (NPV) 99.0%.

CONCLUSIONS

In this prospective and so far largest study on survivin, the marker showed a good NPV and specificity but a low PPV and sensitivity. This was partly due to the low number of cases, which limits the validity of the results. Compliance, urine quality, problems with the assay, and mRNA stability influenced the performance of survivin. However, most issues could be addressed with a more reliable assay in the future. One important finding is that survivin was not influenced by confounders like inflammation and exhibited a relatively low number of false-positives. Therefore, despite the low sensitivity, survivin may still be considered as a component of a multimarker panel.

Для цитирования: Johnen Georg, Gawrych Katarzyna, Bontrup Heike, Pesch Beate, Taeger Dirk, Banek Séverine, Kluckert Matthias, Wellhäußer Harald, Eberle Friedhelm, Nasterlack Michael, Leng Gabriele, Stenzl Arnulf, Brüning Thomas, UroScreen Study Group. Performance of survivin mRNA as a biomarker for bladder cancer in the prospective study UroScreen.. PloS one. 2012. DOI: 10.1371/journal.pone.0035363.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.